The results of the association of genotypes with risk and clinical aspects of CM and survival of CM patients were obtained by analysis of patients from a single public oncology service, in which immunotherapy is not available; therefore, these results should be validated in a larger epidemiological study with CM patients and controls from ethnically diverse populations and in a cohort of patients treated with and without anti-CTLA-4 agents. This evidence concerns the gene CTLA4 and cutaneous mastocytosis.